×
About 16,385 results

ALLMedicine™ Atopic Dermatitis Center

Research & Reviews  4,951 results

A TCM formula VYAC ameliorates DNCB-induced atopic dermatitis via blocking mast cell de...
https://doi.org/10.1016/j.jep.2021.114454
Journal of Ethnopharmacology; Zeng HR, Zhao B et. al.

Jul 31st, 2021 - A Traditional Chinese Medicine (TCM) formula (VYAC) consists of three herbs including Viola yedoensis Makino, herb (Violaceae, Viola), Sophora flavescens Aiton, root (Fabaceae, Sophora) and Dictamnus dasycarpus Turcz, root and rhizome (Rutaceae, D...

Appraisal of Proactive Topical Therapy in Atopic Dermatitis: Pros and Cons.
https://doi.org/10.1007/s40257-021-00629-0 10.1016/S0140-6736(20)31286-1 10.1111/all.12270 10.1111/jdv.15634 10.1016/j.jaci.2010.12.1124 10.1016/j.anai.2020.08.016 10.1016/j.jaci.2017.01.011 10.1080/00015550152572886 10.1016/j.jaci.2016.06.010 10.1111/joim.13235 10.1016/j.jaci.2016.01.027 10.1111/all.13231 10.1111/jdv.16892 10.1111/jdv.15709 10.1111/j.1398-9995.2007.01406.x-i1 10.1111/j.1398-9995.2008.01803.x 10.2340/00015555-2552 10.1016/j.imbio.2007.03.001 10.1111/jdv.14846 10.1111/bjd.16543 10.1016/j.anai.2017.10.039 10.1016/j.jaad.2014.03.023 10.1159/000096915 10.1111/j.1468-3083.2009.03303.x 10.1016/0738-081X(86)90019-2 10.2337/dc18-2158 10.1001/jamadermatol.2020.4968 10.1111/all.13189 10.2340/00015555-3220 10.1111/pai.13394 10.1016/j.jaad.2020.02.079 10.1016/j.jaad.2017.06.042 10.1016/j.jaad.2020.03.011 10.2165/00128071-200506020-00001 10.1185/03007995.2011.582483 10.1046/j.1365-2133.2004.05782.x 10.1159/000065863 10.1067/mpd.2003.65 10.1542/peds.2014-1990 10.1016/j.jaad.2004.08.046 10.2165/00002018-200831030-00001 10.1186/s12887-016-0607-9 10.1111/j.1365-2133.2008.08747.x 10.2147/CLEP.S146442 10.23736/S0392-0488.19.06478-2 10.1016/j.jaad.2017.06.010 10.1016/j.jaad.2016.05.046 10.1007/s40257-020-00510-6 10.5021/ad.2012.24.3.253 10.1111/jdv.13599 10.1016/j.jaad.2017.12.022 10.1046/j.1365-2133.2002.05006.x 10.1136/bmj.326.7403.1367 10.1111/j.1365-2133.2010.10030.x 10.1159/000489125 10.1542/peds.105.4.794 10.1111/j.1365-2133.2008.08807.x 10.1111/j.1365-2133.2010.10141.x 10.5826/dpc.1004a94 10.3109/09546630903401488 10.1111/j.1365-2133.2008.08813.x 10.1111/j.1365-2133.2008.08436.x 10.1111/j.1399-3038.2008.00735.x
American Journal of Clinical Dermatology; Frølunde AS, Thyssen JP et. al.

Jul 30th, 2021 - Atopic dermatitis is a common inflammatory skin disease that can affect both children and adults. It is a chronic disease with recurrent, highly pruritic eczematous lesions. Topical treatment with anti-inflammatory agents is the mainstay of treatm...

Filaggrin-gene mutation has minimal effect on the disease severity in the lesions of at...
https://doi.org/10.1111/1346-8138.16087
The Journal of Dermatology; Ota M, Sasaki T et. al.

Jul 30th, 2021 - Loss-of-function mutations of filaggrin (FLG) gene (FLG) are the strongest known genetic risk factor for atopic dermatitis (AD). It is still debatable how FLG gene mutations and the resulting abnormal amount of FLG protein contribute to skin barri...

Association between Atopic Dermatitis and Hypertension: A Systematic Review and Meta-An...
https://doi.org/10.1111/bjd.20661
The British Journal of Dermatology; Yousaf M, Ayasse M et. al.

Jul 29th, 2021 - Previous studies found conflicting results about the association of atopic dermatitis (AD) with hypertension. Determine whether AD and AD severity are associated with hypertension. A systematic review was performed of published studies in MEDLINE,...

Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic derma...
https://doi.org/10.1080/09546634.2021.1961997
The Journal of Dermatological Treatment; Meher BR, Mohanty RR et. al.

Jul 29th, 2021 - Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder. Though, corticosteroids are the cornerstone of therapy, the Janus kinase inhibitor abrocitinib has shown promise in recent clinical trials for treatment of AD. To assess the...

see more →

Guidelines  8 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Considerations on biologicals for patients with allergic disease in times of the COVID-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300800
Allergy Vultaggio A, Agache I et. al.

Jun 6th, 2020 - The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex pat...

European task force on atopic dermatitis position paper: treatment of parental atopic d...
https://doi.org/10.1111/jdv.15709
Journal of the European Academy of Dermatology and Venere... Vestergaard C, Wollenberg A et. al.

Jun 25th, 2019 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the trea...

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) ...
https://doi.org/10.1111/jdv.14891
Journal of the European Academy of Dermatology and Venere... Wollenberg A, Barbarot S et. al.

Apr 21st, 2018 - This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic revi...

The microbiome in allergic disease: Current understanding and future opportunities-2017...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899886
The Journal of Allergy and Clinical Immunology; Huang YJ, Marsland BJ et. al.

Mar 5th, 2017 - PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and ...

see more →

Drugs  442 results see all →

Clinicaltrials.gov  308 results

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT03703102

May 7th, 2020 - A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically in...

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
https://clinicaltrials.gov/ct2/show/NCT03661866

Apr 28th, 2020 - TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a res...

Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
https://clinicaltrials.gov/ct2/show/NCT03359356

Apr 24th, 2020 - The purpose of this study is to assess whether dupilumab can be a helpful treatment for alopecia areata. This is a randomized, double-blind, placebo-controlled pilot study of a total of 54 subjects with moderate to severe alopecia areata involving...

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
https://clinicaltrials.gov/ct2/show/NCT03720470

Apr 22nd, 2020 - B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy. The efficacy of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once dai...

Eucrisa for Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT03250663

Apr 21st, 2020 - Atopic Dermatitis (AD) affects between 10% and 30% of all children, making it one of the most common childhood diseases. Recent epidemiological studies report a trend toward the increasing prevalence of AD in children. Symptoms of AD include dry, ...

see more →

News  828 results

Proposed Classification Framework for Atopic Dermatitis Unveiled
https://www.medscape.com/viewarticle/954902

Jul 16th, 2021 - The heterogeneous clinical course of atopic dermatitis (AD) and its differing signs, symptoms, burden, and response to treatment can pose a quandary for physicians. Dr Jonathan Silverberg This is behind a new classification framework called DESCRI...

Dupilumab Safe, Effective in Kids 6-11 With Moderate-to-Severe Asthma
https://www.medscape.com/viewarticle/954586

Jul 10th, 2021 - Dupilumab (Dupixent, Sanofi and Regeneron) significantly reduced exacerbations compared with placebo in children ages 6-11 years who had moderate-to-severe asthma in a phase 3 trial. A fully human monoclonal antibody, dupilumab also improved lung ...

Study Provides Insights Into Pediatric Psoriasis Over Two Decades
https://www.medscape.com/viewarticle/954411

Jul 8th, 2021 - Obesity, atopic dermatitis, psychiatric disease, and arthritis are the most common comorbidities among infants, children, and adolescents with psoriasis, while predictors of moderate to severe disease include morphology, non-White race, and cultur...

Expert Shares Practical Considerations for Dupilumab Treatment
https://www.medscape.com/viewarticle/954120

Jul 1st, 2021 - Clinicians who struggle to get dupilumab approved for their patients with moderate to severe atopic dermatitis (AD) are not alone. This scenario was illustrated in a 2020 retrospective study of 179 adults with AD who were cared for at the Universi...

Baricitinib Found Effective for Moderate to Severe AD Out to 52 Weeks
https://www.medscape.com/viewarticle/953944

Jun 29th, 2021 - Baricitinib, at a dose of 2 mg a day, demonstrated efficacy in adults with moderate to severe atopic dermatitis up to 52 weeks, integrated data from two trials demonstrated. "With long-term therapy, the baricitinib 2 mg response remains stable or ...

see more →

Patient Education  17 results see all →